---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-093945"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:17:53.795402+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharmaceuticals raises $50M via ATM equity offering of 2M shares

## Summary
- Sold ~2.019M shares of common stock from Aug 10-21, 2023, for gross proceeds of ~$50M.
- Proceeds, plus existing cash and anticipated $24.4M milestone from Healthcare Royalty Partners, fund operations into 2026.
- Funds to support global commercialization of IMCIVREE (setmelanotide) and rare MC4R pathway clinical programs.
- ATM program originally authorized up to $100M; this drawdown represents half the capacity.

## SEC filing metadata
- accession: 0001104659-23-093945
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923093945/0001104659-23-093945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923093945/tm2324286d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-093945
- JSON: https://secwatch.observer/filing/0001104659-23-093945.json
- Plain text: https://secwatch.observer/filing/0001104659-23-093945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.